Invitrogen™ Cofetuzumab Humanized Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA542173

Catalog No. PIMA542173

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Cofetuzumab is a biosimilar that targets PTK7. CCK4 may function as a cell adhesion molecule. Although it belongs to the insulin receptor subfamily of the Tyr protein kinases, it likely lacks the catalytic activity of a tyrosine kinase. It may be connected to the pathophysiology of colon carcinomas and/or may represent a tumor progression marker. This Type I membrane protein is highly expressed in lung, liver, pancreas, kidney, placenta and melanocytes, but weakly expressed in thyroid gland, ovary, brain, heart and skeletal muscle, and not in colon. It is also expressed in erythroleukemia cells.

Specifications

• Antigen: Cofetuzumab Humanized
• Classification: Recombinant Monoclonal
• Conjugate: Unconjugated
• Gene Alias: hu24; PF-06523435
• Immunogen: Human PTK7.
• Quantity: 100 μg
• Primary or Secondary: Primary
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Form: Liquid
• Target Molecule: Chemical

• Applications: ELISA, SDS-Page
• Concentration: 1.11 mg/mL
• Formulation: PBS with no preservative; pH 7.4
• Host Species: Human
• Purification Method: Protein A/G
• Regulatory Status: RUO
• Target Species: Human
• Product Type: Antibody
• Isotype: IgG1 κ

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov